Sex difference in patients with controlled acromegaly—A multicentre survey
Authors' conclusion
In patients with acromegaly considered controlled, postmenopausal females exhibited higher GH levels than males despite comparable IGF-I levels, which also translated into impaired metabolic health and well-being. Our findings point to the relevance of including GH measurements in the assessment of disease control and suggest that disease-specific sex differences prevail after treatment.
Study context
- Population
- Patients with acromegaly considered controlled after surgery alone or during continued somatostatin receptor ligand (SRL) treatment; mean age 57 (±1.1) years; majority of females postmenopausalor during continued SRL treatment 61
- Participants
- 84 patients
- Exposure
- Females vs males with controlled acromegaly
- Fn = 43
- Mn = 41reference
- Outcome
- Disease control by fasting GH < 1.0 µg/L
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
P = 0.007
Observational data: associations, not effects.
Further findings
Disease control by IGF-I SDS < 2 · comparable
P = 0.71
- AcroQol physical score · impaired in females
- P = 0.05
- Fasting free fatty acid (FFA) · higher in females
- P = 0.03
- Insulin concentrations during oral glucose tolerance test (OGTT) · higher in females
- P = 0.04
Original publication
Sex difference in patients with controlled acromegaly—A multicentre survey. Clin Endocrinol (Oxf). Published 4 May 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →